Dov Bergwerk - 10 Nov 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 16:08:21 UTC
Prior SEC filing
06 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dov Bergwerk
Filing notes and source

Key filing fact

Dov Bergwerk filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 12 Nov 2026.

Key facts

  • This page summarizes Dov Bergwerk's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 12 Nov 2026, 16:08.

Change

  • Previous filing in this sequence was filed on 06 Nov 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001997381 Primary reporting owner

Bergwerk Dov

Relationship
Interim Chief Legal Officer
Address
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HA'NEVIA STREET, TEL AVIV, ISRAEL
Signature
/s/ Dov Bergwerk
Signature date
12 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Restricted Share Units

Award

Transaction value
Shares
+9,433
Change %
Price
$0.000000*
Shares after
9,433
Date
10 Nov 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
9,433
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Footnote F2

Restricted share units were granted on November 10, 2026, with 2,358 vesting on each of November 10, 2027, November 10, 2028 and November 10, 2029, and 2,359 vesting on November 10, 2030.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .